The current stock price of CGC is 1.23 USD. In the past month the price increased by 14.16%. In the past year, price decreased by -47.35%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The company is headquartered in Smiths Falls, Ontario and currently employs 960 full-time employees. The company went IPO on 2010-06-04. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. The firm delivers innovative products from owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. Its segments include Canada cannabis, and Storz & Bickel. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers. In addition, it serves medical cannabis patients globally with principal operations in Canada, Europe and Australia.
CANOPY GROWTH CORP
1 Hershey Dr
Smiths Falls ONTARIO K7A0A8 CA
CEO: David Klein
Employees: 1029
Phone: 18555589333
Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The company is headquartered in Smiths Falls, Ontario and currently employs 960 full-time employees. The company went IPO on 2010-06-04. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. The firm delivers innovative products from owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. Its segments include Canada cannabis, and Storz & Bickel. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers. In addition, it serves medical cannabis patients globally with principal operations in Canada, Europe and Australia.
The current stock price of CGC is 1.23 USD. The price decreased by -4.65% in the last trading session.
CGC does not pay a dividend.
CGC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
CGC stock is listed on the Nasdaq exchange.
13 analysts have analysed CGC and the average price target is 2.81 USD. This implies a price increase of 128.62% is expected in the next year compared to the current price of 1.23.
CANOPY GROWTH CORP (CGC) will report earnings on 2026-02-05, before the market open.
ChartMill assigns a technical rating of 1 / 10 to CGC. When comparing the yearly performance of all stocks, CGC is a bad performer in the overall market: 88.78% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to CGC. While CGC seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months CGC reported a non-GAAP Earnings per Share(EPS) of -2.03. The EPS increased by 58.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.07% | ||
| ROE | -52.42% | ||
| Debt/Equity | 0.33 |
13 analysts have analysed CGC and the average price target is 2.81 USD. This implies a price increase of 128.62% is expected in the next year compared to the current price of 1.23.
For the next year, analysts expect an EPS growth of 94.86% and a revenue growth 2.14% for CGC